# Terns Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/terns-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Foster City, US
- Website: www.ternspharma.com
- Total disclosed funding: $208M
- Latest round: Series C (Dec 29, 2020)
- Investors on record: 8

## About

Founded in 2017 and based in California, US, Terns Pharmaceuticals, Inc. operates as a biotechnology company that develops treatments for patients with chronic liver diseases. The company was founded by CEO Senthil Sundaram. Terns Pharmaceuticals has raised a total of USD 197 million over 3 funding rounds. In February 2021, Terns Pharmaceuticals announced the pricing of upsized Initial Public Offering for USD 127.5 million and selling 7.5 million shares at USD 17 per share on the NASDAQ.

Terns Pharmaceuticals operates as a clinical-stage biopharmaceutical company that develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ program called TERN-101 a liver-distributed, nonsteroidal, non-bile acid FXR agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient intestinal FXR activation.

Terns Pharmaceuticals plans to list on the Nasdaq global select market under the ticker symbol TERN.

## Funding rounds

- Series C, Dec 29, 2020, $98M — OrbiMed Advisors, Vivo Capital, Samara Capital, Lilly Asia Ventures, Suvretta Capital Management, Eli Lilly & Company, Deerfield Management
- Series B, Oct 30, 2018, $80M — OrbiMed Advisors, Vivo Capital, Lilly Asia Ventures, Decheng Capital
- Series A, Apr 1, 2017, $30M — Lilly Asia Ventures

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B, Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B
- Samara Capital (https://capitalatlas.ai/funds/samara-capital) — Series C
- Suvretta Capital Management — Series C
- Eli Lilly & Company — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C